ESMO China’s Voice丨Dr. Hongyan Tong’s Team: IMM01 Combined with Azacitidine as a New First-Line Treatment for CMML Shows 72.7% ORR in Phase II Study!

ESMO China’s Voice丨Dr. Hongyan Tong’s Team: IMM01 Combined with Azacitidine as a New First-Line Treatment for CMML Shows 72.7% ORR in Phase II Study!

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13-17 in Barcelona, Spain. As one of the largest and most prestigious global clinical oncology conferences, it showcased groundbreaking research from experts around the world, advancing the field of oncology. In the hematologic malignancy space, this year's ESMO also featured many key advancements, including research from China. One such study, led by Dr. Hongyan Tong from The First Affiliated Hospital of Zhejiang University Medical College, was selected for an oral presentation. The study explored the efficacy of Timdarpacept (IMM01) combined with azacitidine (AZA) as a first-line treatment for chronic myelomonocytic leukemia (CMML) (801 MO). Hematology Frontier had the opportunity to interview Dr. Maria Ma, one of the team members, who provided an in-depth explanation of the study.
ESMO China’s Voice丨Dr. Fei Ma: Breakthrough Advances in Breast Cancer Treatment with New Trop-2 ADC Drug ESG401

ESMO China’s Voice丨Dr. Fei Ma: Breakthrough Advances in Breast Cancer Treatment with New Trop-2 ADC Drug ESG401

The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting will be held from September 13-17 in Barcelona, Spain. At this upcoming ESMO 2024 conference, Dr. Fei Ma from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College will present two Mini Oral reports (344MO, 349MO) on the novel Trop-2 antibody-drug conjugate (ADC) ESG401. These two studies not only highlight the significant efficacy of ESG401 in HER2-negative breast cancer with brain metastases but also reveal its broad potential application across different subtypes of metastatic breast cancer. This provides new treatment options for breast cancer patients and opens new directions for the research and development of Trop-2 ADC drugs. Oncology Frontier invited Dr. Fei Ma to introduce the key aspects of these two studies, and we look forward to his exciting presentation at ESMO 2024, contributing Chinese insights and expertise to global breast cancer treatment.
ESMO International Perspective | Dr. Hitomi Sakai: The OLZ-based Triple Therapy Offers a New Strategy for Nausea and Vomiting in Breast Cancer Patient

ESMO International Perspective | Dr. Hitomi Sakai: The OLZ-based Triple Therapy Offers a New Strategy for Nausea and Vomiting in Breast Cancer Patient

At the 2024 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Hitomi Sakai from the Advanced Cancer Translational Research Institute in Japan reported on the significant efficacy of the OLZ-based triple therapy in preventing treatment-related nausea and vomiting (NV) in patients treated with T-DXd, providing an important reference for clinical practice. After the conference, Dr. Hitomi Sakai was interviewed by Oncology Frontier, where she introduced the research process and related results.
Dr. Peter Schmid：KEYNOTE-522 Study OS Results Update, Pembrolizumab Reshapes the Treatment Landscape for Early TNBC patients

Dr. Peter Schmid：KEYNOTE-522 Study OS Results Update, Pembrolizumab Reshapes the Treatment Landscape for Early TNBC patients

At the 2024 ESMO Congress, Dr. Peter Schmid from Barts Cancer Institute, Queen Mary University of London shared the overall survival data from the KEYNOTE-522 study with a follow-up of 75.1 months. The long-term follow-up results of the study showed that the combination of immunotherapy and chemotherapy significantly extended the event-free survival and overall survival of patients with triple-negative breast cancer, reducing the risk of recurrence and death. This breakthrough not only reaffirms the therapeutic position of immunotherapy in early triple-negative breast cancer but also points the way for further optimizing treatment plans in the future, bringing longer survival hopes for patients. Oncology Frontier specially invited Dr. Peter Schmid to share the relevant data.
Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

In April 2024, the 115th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA. As a global bellwether for new cancer drug development, the AACR meeting showcased numerous cutting-edge research findings in the field of oncology. One such study, conducted by Dr. Lin Shen's team from Peking Cancer Hospital, evaluated camrelizumab combined with chemotherapy as a neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). This single-center, randomized, Phase II trial was selected for poster presentation at the conference, and Oncology Digest - Digestive Oncology News has summarized the key findings for readers.
Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

The reduction of hepatitis B surface antigen (HBsAg) levels in treated chronic hepatitis B (CHB) patients is closely linked to decreased risks of cirrhosis and even liver cancer. However, spontaneous HBsAg clearance occurs in less than 1% of patients per year. As CHB prevention and treatment guidelines continue to evolve both domestically and internationally, more patients are now pursuing "functional cures" through nucleos(t)ide analogs (NAs) combined with or followed by pegylated interferon (PEG-IFN) treatment. This approach offers the possibility of reducing or eliminating long-term or lifelong medication use. Clinically, even when patients use similar regimens aimed at achieving a functional cure, many continue to struggle along the difficult path to achieving HBsAg seroclearance, let alone reaching the ideal treatment endpoint of HBs seroconversion. Thus, understanding and recognizing the potential factors influencing functional cure is crucial for timely evaluation and intervention. This article summarizes the possible factors affecting CHB functional cure based on both domestic and international research to date.
Dr. Lin Shen: Focusing on Innovative Targets, Advancing Translational Research, and Promoting the Healthy Development of Digestive System Tumors

Dr. Lin Shen: Focusing on Innovative Targets, Advancing Translational Research, and Promoting the Healthy Development of Digestive System Tumors

In June 2024, the 14th Annual Meeting of the Chinese Gastrointestinal Oncology Group (CGOG) and the Peking University Digestive Tumor Forum was held in Beijing. With the theme of "Innovation, Win-Win, Excellence," the conference focused on precision diagnosis and treatment, as well as translational research in digestive system tumors. It also covered the latest research progress and challenges in clinical practice. During the event, a reporter from Oncology Frontier conducted an exclusive interview with the conference chair, Dr. Lin Shen from Peking Cancer Hospital. Below is the interview for readers.
SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4th to 7th, 2024, gathering top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new therapeutic strategies. At the conference, Dr. Eunice Wang from the Roswell Park Comprehensive Cancer Center in the United States presented the latest developments in the research and development of Menin inhibitors. For this, 'Oncology Frontier - Hematology Frontier' specially interviewed Dr. Eunice Wang and provided a wonderful interpretation around this topic.
Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

Primary liver cancer ranks as the fourth most common malignancy and the second leading cause of cancer-related deaths in China, posing a severe threat to people's lives and health. Early detection, diagnosis, and treatment are crucial for improving treatment outcomes. In 2019, Dr. Feng Shen and Dr. Tian Yang research team from Eastern Hepatobiliary Surgery Hospital, collaborating with 11 renowned tertiary hospitals in China, developed the ASAP (Alpha-Fetoprotein, Age, Sex, and PIVKA-II) liver cancer risk assessment model, making a significant contribution to Chinese clinical practice.